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Objective. To evaluate the efficacy and safety of the Xen Gel Stent and provide a macro- and microscopic analyses of
bleb morphology. Methods. A prospective 12-month study on patients with primary open-angle glaucoma. Patients
underwent implantation of the XEN Gel Stent (Allergan INC, Dublin, Ireland) either alone or combined with a
cataract surgery. Biomicroscopy, in vivo confocal microscopy (IVCM), and anterior segment-optical coherence
tomography (AS-OCT) were used to assess bleb morphology. Safety parameters were adverse events, best corrected visual
acuity, visual field, and corneal endothelial cell loss. A postoperative IOP≤ 18mmHg without or on medications was
respectively defined as complete and qualified success while an IOP≥ 18mmHg was defined as failure. Results. Twelve
eyes of 11 patients were evaluated. At one year, 5 out of 10 patients available achieved a complete success while five
were qualified success. AS-OCT showed that bleb wall reflectivity was significantly higher in the failure group; IVCM
revealed that stromal density was significantly lower in the success group. No safety issues were recorded. Conclusion.
Implantation of the XEN Gel Stent appears to be a safe and effective procedure. AS-OCT and IVCM may be helpful in
bleb assessment.
1. Introduction
Since the mid-1960s, trabeculectomy has been the gold stan-
dard in the treatment of glaucoma [1]. A plethora of pub-
lished studies highlight the efficacy of trabeculectomy,
including a 20-year follow-up study of trabeculectomy in
234 patients by Landers et al., who found that trabeculectomy
survival was approximately 60% with no topical medication
and approximately 90% with topical medication [2]. The
procedure does, however, have limitations.
Findings from the National Survey of Trabeculectomy
which included 1240 cases showed that early complications
were reported in 46.6% of cases and late complications in
42.3% cases. The most frequent early complications were
hyphema (24.6%), shallow anterior chamber (23.9%),
hypotony (24.3%), wound leak (17.8%), and choroidal
detachment (14.1%). The most frequent late complications
were cataract (20.2%), visual loss (18.8%), and encapsu-
lated bleb (3.4%) [3].
In an attempt to mitigate the intra- and postoperative
complications associated with traditional glaucoma surgery,
several newminimally invasive glaucoma surgeries have been
developed. These include ab interno canaloplasty (ABiC™,
Ellex Medical Lasers Ltd, Adelaide, Australia, the Trabec-
tome® (NeoMedix Inc., Tustin, California), the iStent®
(Glaukos, Laguna Hills, California) the Hydrus™ (Ivantis,
Irvine, California), and the CyPass Suprachoroidal Micros-
tent (Transcend Medical, Menlo Park, California) [4, 5].
Another minimally invasive device known as the XEN
Gel Stent (Allergan INC, Dublin, Ireland) is a long flexible
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tube made of chemically treated, cross-linked gelatin; one
end of which is placed in the anterior chamber allowing fluid
to exit the eye and form a subconjunctival bleb at the other
end of the tube [6]. Aqueous outflow is determined by the
bore (45μm) and length (6.0mm) of the stent; these particu-
lar dimensions were selected because they represent the best
ratio for optimal outflow and a low rate of complications.
Traditional ab externo trabeculectomy requires an incision
in both the conjunctiva and sclera which may cause bleeding
and scarring, potentially leading to a bleb failure. In contrast,
the XEN Gel Stent is implanted using an ab interno
approach. Thus, the device is designed to have similar effi-
cacy as invasive gold standard procedures, but has the poten-
tial to significantly lower traditional complication rates [7].
Findings from a prospective, nonrandomized, multicenter
evaluation of multiple XEN Gel Stent models showed that
there was a 40% reduction in IOP at 36 months and a 74%
reduction in antiglaucomatous medications. Moreover, the
outcomes of stand-alone implants and implants combined
with cataract surgery were similar [8].
One of the keys to successful filtering surgery is the devel-
opment of a bleb in the postoperative period. Morphologic
changes to the developing filtering bleb after surgery may
help to predict early treatment failure and guide bleb revision
and management [9]. An early study by Addicks et al., for
example, found that failed trabeculectomy blebs had dense
collagenous connective tissue in their walls, while in func-
tioning blebs, the subepithelial connective tissue was loosely
arranged and contained histologically clear spaces [10].
Currently, there is no data describing bleb morphology
following implantation of the XEN Gel Stent. Consequently,
we undertook a 12-month prospective study to evaluate effi-
cacy, safety, and bleb morphology following implantation of
the device, either alone or combined with cataract surgery,
in patients with POAG.
2. Methods
2.1. Study Design and Patients. This was a single-center, pro-
spective study undertaken at the Eye Clinic of the Ophthal-
mic Hospital in Turin, Italy. Patients were fully informed of
the purpose of the study, surgical technique, potential risks,
and possible outcomes. The study received approval from
the local Ethics Board Committee, and written informed con-
sent was obtained before the study procedure and data collec-
tion according to the principles specified in the Helsinki
protocol and its amendments.
Patients eligible for inclusion in the study were those with
a diagnosis of POAG with uncontrolled IOP (defined as
≥18mmHg and ≤33mmHg in between one and four anti-
glaucoma medications) and a healthy and mobile superior
bulbar conjunctiva. Additionally, all included patients had
the stent protruding at least 1mm and no more than 2mm
in the anterior chamber as assessed by gonioscopy and at
least 3mm of the stent measurable out of the scleral track.
Patients were excluded from the study if they had undergone
previous corneal and glaucoma surgeries, had a diagnosis of
glaucoma other than POAG, corneal opacities, or ocular dis-
ease other than glaucoma.
Postoperative surgery evaluation was performed basing
on IOP and use of antiglaucoma medications; patients
achieving a postoperative IOP of <18mmHg without anti-
glaucoma medications were defined “complete success” and
were part of the success group. The failure group was com-
posed by patients with a postoperative IOP≤ 18mmHg on
antiglaucoma medications, namely “qualified success,” and
by those with a postoperative IOP≥ 18mmHg.
2.2. Endpoints/Outcome Measures. The primary objective of
this study was to investigate bleb morphology through the
follow-up and to find possible prognostic factors of surgical
success.
The secondary objective was to assess the safety and
efficacy of XEN Gel Stent implantation. Efficacy was
assessed by reductions in IOP and medication use follow-
ing implantation of the device. Safety was determined by
the incidence of adverse events, loss of best corrected
visual acuity (BCVA), Humphrey visual field parameters,
and endothelial cell count.
2.3. Pre- and Postoperative Evaluations. All patients under-
went a detailed clinical assessment before and after implanta-
tion of the gel stent. Preoperatively, patients underwent a slit
lamp examination, gonioscopy (to classify the iridocorneal
angle according to Shaffer grading scale), pachymetry, and
tonometry. A full medical history, including medication
use, was recorded.
Conjunctiva/bleb evaluation with biomicroscopy was
performed at 1 week and at 1, 3, 6, and 12 months postoper-
atively. Specular microscopy (Konan Cell Check XL; Konan
Medical, Irvine, CA, USA) was performed preoperatively
and at 1, 3, 6, and 12 months postoperatively. CD (cell den-
sity), SD (standard deviation), CV (coefficient of variation),
and 6A (hexagonality coefficient) were evaluated. Humphrey
24-2 SITA-standard visual field testing (Carl Zeiss Meditec,
Dublin, CA, USA) was undertaken preoperatively and at 6
and 12 months after surgery. In vivo confocal microscopy
(IVCM) was performed preoperatively and at 3, 6, and 12
months postoperative, while AS-OCT was undertaken at 1,
3, 6, and 12 months postsurgery.
Need for further intervention (e.g., needling or trabecu-
lectomy) was based on failure in IOP control.
2.4. Assessment of Bleb Morphology
2.4.1. Biomicroscopy. Biomicroscopy was used to measure
bleb area in clock hours (1–12), vascularization (0–4 accord-
ing to a modified and Moorfields Bleb Grading [11]), and
borders (diffuse/well defined). Two clinicians independently
evaluated the bleb. If the difference in terms of evaluation
was within one, a mean was performed; if the difference
was higher, the bleb was reevaluated by a third operator
and a mean was taken.
2.4.2. IVCM. IVCM was performed with the HRT II/Rostock
Cornea Module (RCM; Heidelberg Engineering, Inc,
Franklin MA, USA). Before the IVCM examination, one
drop of Novesine 0.4% (oxybuprocaine 0.4%) was instilled
into the lower conjunctival fornix. The patient was then
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seated in front of the IVCM with the head set steady in a
headrest. The eye was properly aligned to obtain tangential
optical section of the whole upper bulbar conjunctiva by
means of a dedicated target mobile bright red light of
the instrument that the patient fixed with the contralateral
eye. A digital camera provided a lateral view of the eye and
the position of the objective lens on the surface of the eye
for each scan. Manual frame acquisition throughout the
upper bulbar conjunctiva at approximately 7mm from the
superior limbus in down gaze was performed. The superona-
sal conjunctiva was examined at all postoperative visits;
Results were reported as the average of three best images
selected by the IVCM operator. The main outcome measures
of IVCM were mean intraepithelial microcyst area, mean
intraepithelial microcyst density, and subepithelial connec-
tive tissue density in terms of reflectivity (grayscale).
2.4.3. AS-OCT. AS-OCT was performed using the RTVue-
100 (Optovue, Inc, Fremont, CA, USA). For the examina-
tion, the patient was asked to gaze downwards and the
upper eyelid was gently elevated, exposing the bleb as
much as possible. AS-OCT longitudinal scans were used
to check the appropriate placement of the device and
properly orient the cross-scans, which in turn were used to
perform a macroscopic analysis of bleb morphology. Three
cross-scans were performed at final portion of the gel stent,
and the average was considered in the calculations.
Variables of bleb morphology assessed by AS-OCT were
stromal density of the bleb wall (bleb wall reflectivity, gray-
scale), bleb wall thickness at the thinnest point, maximal
height of the bleb, and total area of the hyporeflective cystic
spaces. The best image obtained in a series of three images
was analyzed.
IVCM measurements of the mean intraepithelial
microcyst area and the subepithelial connective tissue den-
sity and AS-OCT measurements of the total area of the
hyporeflective cystic spaces and of the bleb wall reflectivity
were calculated using ImageJ software (http://rsb.info.nih.
gov/ij/download.html). The density of the microcysts showed
by IVCMwas evaluated using themanual cell counting proce-
dure provided in the HRT software. The bleb wall thickness
and the maximal height of the bleb were assessed using the
AS-OCT software.
Both the IVCM and AS-OCT operators were masked for
all clinically relevant data.
2.5. Study Device. The XEN Gel Stent is indicated for the
reduction of IOP in patients with POAG where previous
medical treatments have failed. The device is 6mm long
and 45μm wide and is injected through a small self-sealing
corneal incision using a simple, preloaded injector. The
XEN Gel Stent is made of a permanent, soft, collagen-
derived gelatin. Upon implantation, it allows diffuse outflow
of aqueous from the anterior chamber into the nondissected
tissue of the subconjunctival space [7].
2.6. Surgical Procedure. All surgeries were performed under
peribulbar anaesthesia. Thirty minutes before surgery,
0.02% mitomycin C (MMC) was injected into the
subconjunctival space in the quadrant selected for implanta-
tion of the device. The conjunctiva in the superonasal quad-
rant was marked 3mm from the limbus as a guide for the exit
point of the device. A 1.5mm inferotemporal corneal inci-
sion was then made 1mm anterior to the limbus. Following
injection of cohesive ophthalmic viscosurgical device
(OVD, Healon GV), a superonasal paracentesis was created.
Using an ab interno approach, the preloaded inserter needle
was passed through the cornea and the needle was directed
across the anterior chamber and implanted in the target
quadrant, connecting the subconjunctival space to the ante-
rior chamber. Every effort was made to avoid contact with
the corneal endothelium, crystalline lens, and iris during
the implantation procedure. If the implant procedure was
combined with cataract surgery, successful and uncompli-
cated cataract surgery was performed prior to the AqueSys
XEN implantation. Once the device had been implanted,
the anterior chamber was flushed with balanced saline solu-
tion to remove viscoelastic fluid followed by hydro sealing
of the corneal incision. If cataract surgery was performed, a
10–0 single stitch suture was used for phaco entry.
Patients were instructed to refrain from rubbing their
eyes for a few weeks following surgery. BAK-free fluoro-
quinolone was prescribed QID during the first week post-
operative. Prednisolone acetate 1% or equivalent, or
difluprednate 0.05% without BAK, was prescribed QID,
1–4 weeks postsurgery, TID, week 5 postoperative, BID,
week 6 postoperative, and QD, 7–12 weeks postsurgery.
2.7. Statistical Analysis. All statistical analyses were per-
formed using the Analyse-it® software for Microsoft Excel.
Continuous variables were checked to meet the normality
conditions of Shapiro-Wilk test. Paired and unpaired t-tests
were used for continuous variables. A Wilcoxon test was
employed for all other analyses. Statistical significance was
set at p < 0 05.
3. Results
Twelve eyes of 11 patients with uncontrolled POAG were
included in the analysis. The clinical and demographic base-
line characteristics are summarized in Table 1. Ten eyes
underwent Xen Gel Stent implantation as solo procedure
Table 1: Patient demographics and baseline characteristics.
Patients 11
Eyes 12
Gender (M/F) 5/6
Age (years) 71.3± 10.0
CCT (μm) 548.7± 44.9
Snellen BCVA 6.38± 3.23/10
MD (dB) −12.5± 8.69 dB
Preoperative IOP (mmHg) 21.79± 2.8mmHg
Number of antiglaucoma
medications at baseline
2.92± 1.16
BCVA: best corrected visual acuity; CCT: central corneal thickness;
MD: mean deviation of visual field test.
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while 2 eyes underwent Xen Gel Stent implantation com-
bined with cataract surgery.
3.1. IOP and Medication Use. At six months postoperative,
surgery was a complete success for 8/12 eyes (66.67%),
a qualified success for 3/12 eyes (25%), and a failure for
1/12 eyes (8.33%). At 12 months postoperative, five of 10 eyes
available for follow-up were in the complete success group;
the others were a qualified success requiring one medica-
tion. Overall, a 31.62% reduction in IOP and 82.88% in
medication versus baseline was achieved (both p < 0 001)
(Figures 1 and 2; Table 2).
Six eyes required needling: 3 at 1 month and 3 at 6
months (4 “qualified success” and 2 “complete success”).
One patient was lost to follow-up at the seven-month visit,
and one patient underwent trabeculectomy due to poor
IOP control nine months after stent implantation.
3.2. Biomicroscopy. Mean bleb area ranged between 2.25
± 0.45 (1 week) and 2.9± 1.37 (1 year) clock hours. Mean
height of the bleb (range 0–3) ranged between 1.67± 0.49
(1 week) and 1.83± 0.58 (1 year). Borders appeared diffused
in all patients at all follow-up examinations. Bleb vasculariza-
tion (scale 0–4 according to a modified Moorfields Bleb
grading) was reduced significantly from 1 week (1.58± 0.67)
to 1 year postoperative (1.1± 0.32) (p = 0 04).No significant
differences between the success and the failure groups at
any visit were recorded.
3.3. IVCM and AS-OCT. Microcysts at the superonasal
conjunctiva detected by IVCM before surgery were scattered,
with an optically clear structure, round or oval-shaped
surrounded by a hyperreflective wall with no signs of clus-
tering. Postoperatively, microcysts were of different shapes
and sizes and were clustered and surrounded by a low
reflective wall (Figure 1).
In the postoperative period, mean microcysts area and
density increased significantly, whereas the subepithelial
connective tissue density decreased significantly till the
6th month and then increased again till the end of the
follow-up period. At one year postoperative, the area and
density of microcysts at the superonasal conjunctiva were
different as compared to the baseline (Table 3, p < 0 05
and p = 0 05, resp.).
Comparing the “success” and “failure” groups (Table 4),
the area and density of epithelial microcysts were higher in
success group but without reaching statistical significance
(p > 0 05). At 12 months postoperative, stromal density
was significantly lower in the success group (p < 0 05).
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Figure 1: Mean IOP through 12 months postoperative.
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Figure 2: Mean number of antiglaucoma medications through 12 months postoperatively.
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AS-OCT scans at different follow-up times are shown in
Figure 3. There were no significant changes in any of the
variables assessed using AS-OCT through the whole post-
operative period (p > 0 05 for all parameters) (Table 5).
Comparing the success and failure groups (Table 6), the
maximal height of the bleb and total area of the cystic
hypoechoic spaces were significantly higher, whereas bleb
wall reflectivity was significantly lower (p < 0 05) in function-
ing versus nonfunctioning blebs at six months postoperative.
At one year postoperative, bleb wall reflectivity was signifi-
cantly different between the two groups (p < 0 05), that is,
higher in the failure group.
3.4. Safety. There was no statistically significant difference
in Humphrey visual field testing or BCVA at 12 months
postoperative versus baseline (p > 0 05) (Table 7). There
were also no significant changes in endothelial cell density
over one year postoperative (p > 0 05); however, cell hexa-
gonality increased significantly (p = 0 031). No other safety
issues related to the procedure or to the study device were
observed.
4. Discussion
The XEN Gel Stent is a minimally invasive device
designed to offer the same benefits as traditional, gold
standard filtering surgeries. A recently published paper
reported an IOP reduction around 30% with a reduction
of 2.9 glaucoma medications per patient at one year [12].
A previous study with a longer follow-up shows that implan-
tation of the device was associated with a 40% reduction in
IOP at 36 months and a 74% reduction in antiglaucomatous
medications [8]. In our series, we observed a 31.62% reduc-
tion in IOP and an 82.88% reduction in medications use.
All patients achieved an IOP < 18mmHg at 12 months post-
operative; five of 10 evaluable eyes required one medication
to maintain IOP.
The primary aim of our case series was to examine
bleb morphology by means of a variety of imaging tech-
niques, as previously done following trabeculectomy. A slit
lamp examination is frequently used to assess bleb mor-
phology; however, in some cases, there is no correlation
between the bleb appearance and the IOP, leading to difficul-
ties in assessing the filtering ability and the signs of failure
(i.e., scarring processes). Consequently, ophthalmologists
are increasingly turning to advanced imaging technologies
to gain a clearer understanding of bleb morphology and, in
turn, help them differentiate between a functioning and a
failing/failed bleb.
Biomicroscopy evaluation of the Xen Gel Stent bleb can
be difficult due to the smaller dimensions of the bleb as com-
pared to the blebs typically observed after trabeculectomy. In
vivo confocal microscopy showed that, overall, there were
significant changes within the conjunctiva over 12 months
postoperative. On the other hand, no significant changes in
any variables assessed using AS-OCT were found; this can
Table 2: IOP and number of medications over one year postoperatively.
Baseline 1 month 3 months 6 months 1 year
IOP
Number of
medications
IOP
Number of
medications
IOP
Number of
medications
IOP
Number of
medications
IOP
Number of
medications
21.8± 2.8 2.92± 1.16 19.8± 10.3 19.8± 10.3 0.17± 0.58 13.8± 5.2 0.67± 0.98 16.0± 4.8 0.50± 0.90 14.9± 2.1 0.50± 0.53
Table 3: In vivo confocal microscopy data preoperatively and after XEN Gel Stent implantation.
MMA MMD SCTD
Preop 773.3± 1361.6 7.64± 15.12 91.25± 23.20
Month 3 15564.9± 12264.1 56.75± 44.90 83.85± 14.90
Month 6 16255.1± 14056.7 68.03± 37.08 70.30± 20.71
Month 12 12159.4± 16634.5 77.87± 95.63 96.55± 32.38
p value preop versus month 6 0.002 < 0.001 0.037
p value preop versus month 12 0.059 0.003 0.679
MMA: mean microcysts area; MMD: mean microcysts density; SCTD: subepithelial connective tissue density. Data are expressed as mean ± standard deviation.
For the analysis of variables, the Student t-test was applied. p values <0.05 were considered statistically significant.
Table 4: In vivo confocal microscopy data: success versus failure groups.
MMA MMD SCTD
Month 6 Month 12 Month 6 Month 12 Month 6 Month 12
Success group 19,407± 15,796 12,502± 19,633 50.12± 30.16 86.47± 91.47 62.12± 18.02 72.69± 14.53
Failure group 13,665± 8120 11,816± 15,389 44.17± 8.42 69.27± 109.66 86.64± 16.75 120.4± 26.91
p value success versus failure 0.20 0.95 0.35 0.79 0.05 0.01
MMA: mean microcysts area; MMD: mean microcysts density; SCTD: subepithelial connective tissue density. Data are expressed as mean ± standard deviation.
For the analysis of variables, the Student t-test was applied. p values < 0.05 were considered statistically significant.
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be eventually explained by the absence of a baseline AS-OCT
analysis at the intended site of implantation.
Ciancaglini and colleagues proposed a microscopic and
macroscopic bleb analyses by undertaking a clinical, IVCM,
and AS-OCT assessments of filtering blebs after trabeculect-
omy [13]. In the present study, we performed both IVCM
and AS-OCT analyses of the Xen Gel Stent bleb to detect
morphologic features related to stent efficacy. We investi-
gated tissue rearrangement and anatomical modifications
induced by stent implantation as well as early signs of the
subconjunctival wound healing process responsible of sur-
gery failure.
In this study, IVCM showed significant changes within
the conjunctival stroma in all patients one year after surgery.
Microcysts within the bleb wall epithelium, firstly detected by
Labbè et al. [14] following successful trabeculectomy, were
significantly increased in density and area at the 6 months
of follow-up visit, suggesting a progressive aqueous percola-
tion after stent implantation. Additionally, at 6 months, stro-
mal reflectivity was significantly lower in the whole superior
bulbar conjunctiva with respect to previous observations,
suggesting a slower manifestation of tissue rearrangement
in deeper layers.
Comparing successful and failed blebs at 12 months, the
stromal density was significantly lower in the success group.
Increased microcysts and loosely arranged connective tis-
sue/low stromal reflectivity are suggestive of new or increased
alternative aqueous humor outflow induced by the stent
AS-OCT at 1 month after Xen Gel Stent implantation
AS-OCT at 3 months after Xen Gel Stent implantation
AS-OCT at 6 months after Xen Gel Stent implantation
AS-OCT at 1 year after Xen Gel Stent implantation
Pre Post
Pre Post
Figure 3: Pre- and postoperative AS-OCT scans.
Table 5: Anterior segment OCT data over 1 year postoperatively.
Maximal height
of the bleb
Total area of the hyporeflective
cystic spaces
Bleb wall
reflectivity
Bleb wall
thickness
Month 1 492.4± 281.8 802.1± 96.0 136.6± 49.7 206.3± 228.8
Month 6 586.0± 418.7 828.8± 991.0 129.6± 34.2 102.7± 36.6
Month 12 462.4± 328.1 555.0± 572.6 130.7± 55.7 158.8± 76.3
p value (month 1 versus 12) NS NS NS NS
Data are expressed as mean ± standard deviation. For the analysis of variables, the Student t-test was applied. p values < 0.05 were considered statistically
significant. NS: nonsignificant.
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implantation. Our data show that conjunctival microcysts
existed prior to stent implantation. Different hypotheses on
epithelial microcysts have been drawn; they are supposed to
be hallmarks of transcleral and transconjunctival aqueous
percolation or the result of an epithelial disruption, in partic-
ular a degeneration at goblet cells level [15].
Ciancaglini et al. [13] previously reported that all IVCM
parameters correlated well with the bleb functionality follow-
ing trabeculectomy whereas, among the AS-OCT parame-
ters, only the bleb wall reflectivity was significantly related
to filtering capability. Similarly, in the present study, AS-
OCT showed that one year after surgery, there were no sig-
nificant differences between the success and failure groups
except for bleb wall reflectivity, which was higher in nonfunc-
tioning blebs. An early study by Addicks et al. [10] found that
encapsulated blebs (where the bleb wall was composed of
dense collagenous connective tissue) had high reflectivity,
while Leung and colleagues noted low–medium reflectivity
in the OCT images of functioning blebs [16].
Considering the AS-OCT cross-sections, neither biomet-
ric parameters nor bleb wall reflectivity changed over time,
suggesting that the bleb probably acquires its definitive mac-
roscopic appearance by the first month after stent implanta-
tion. At the third and sixth months postoperative, the
maximal height of the bleb and the total area of cystic hypoe-
choic spaces were significantly higher in the success group
probably due to a higher amount of fluids in filtering blebs.
Bleb stromal reflectivity was significantly different between
the two groups at all follow-up visits. We hypothesize that
the density of the bleb connective tissue may be the deter-
mining factor for the long-term functionality of the bleb.
Longitudinal scans, AS-OCT, proved to be useful in
checking the correct placement of the device and were useful
in the present study to evaluate consistent areas of the bleb
over the follow-up.
Additionally, AS-OCT, as compared to biomicroscopy
and IVCM, provided “intrableb imaging” and a macroarchi-
tectural analysis of the bleb as a whole.
This study presents some limitations. It has a small sam-
ple size, has a relatively short follow-up, and lacks an early
postoperative evaluation to more stringently monitor the
bleb development. A more standardized approach in bleb
evaluation with imaging techniques is also warranted.
The presence of inflammatory cells, indicators of
inflammation, and subsequent fibrosis in the conjunctival
epithelium was not methodically investigated; however, it
could provide a valuable predictive tool and deserves
further investigations. It is also possible that AS-OCT
may misrepresent bleb structure and artifacts [17].
Finally, the sample size is small and the follow-up is
quite short; larger scale studies with longer follow-up
are required.
To the best of our knowledge, this is the first study to
evaluate bleb morphology following implantation of the
XEN Gel Stent. We showed the wound healing may proceed,
but by using biomicroscopy, the bleb may not appear to
change, resulting in aqueous outflow decrease and an
increase in IOP. Consequently, we propose a combined clin-
ical and instrumental approach that could enable the clini-
cian to functionally evaluate the XEN Gel Stent filtering
bleb in the postsurgical follow-up.
Our findings also show that there were statistically signif-
icant reductions in both IOP and medication use following
implantation of the XEN Gel Stent in this group of POAG
patients, and no safety issues related to the procedure or to
the study device were observed. Overall, implantation of the
XEN Gel Stent appears to be an effective and safe procedure
for the treatment of POAG.
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